Feng, M., Moran, J.M., Koelling, T., et al. (2011) Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. International Journal of Radiation Oncology, Biology, Physics, 79, 10-18.

has been cited by the following article:

• TITLE: Radiation associated coronary occlusion: Overlooked as trastuzumab-induced cardiomyopathy

  AUTHORS: Ugur Turk, Veysel Yavuz, Nurullah Cetin

  KEYWORDS: Cardiomyopathy; Trastuzumab; Radiation

  JOURNAL NAME: Open Journal of Internal Medicine, Vol.3 No.1, March 22, 2013

  ABSTRACT: Trastuzumab is an agent used for receptor-positive breast cancer. Up to a third of patients treated with trastuzumab might develop cardiomyopathy. Many patients with breast cancer have taken pre- or co-administration of mediastinal radiotherapy. Both of treatment modalities have toxic effects on myocardium. It may result with diagnostic confusion between radiation-induced CAD (riCAD) and trastuzumab cardiomyopathy in the case with dilated cardiomyopathy. TTE may offer clues of differential diagnosis.